OTCMKTS:RHHBY - Roche Holdings AG Basel Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$32.58 -0.11 (-0.34 %)
(As of 04/22/2019 11:56 AM ET)
Previous Close$32.69
Today's Range$32.57 - $32.89
52-Week Range$26.30 - $34.98
Volume239,835 shs
Average Volume831,128 shs
Market Capitalization$222.63 billion
P/E Ratio14.04
Dividend Yield2.08%
Beta0.52
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases. The company's diagnostic solutions include blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol and coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis, heterogeneous immunochemistry, homogeneous immuno assay, immunology, and infectious disease solutions; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control services; real-time PCR diagnostic systems; urinalysis; and serum work area and workflow solutions. In addition, it offers gene expression, gene sequencing, and real time PCR systems for researchers. The company licenses its products or technologies to third parties. Roche Holding AG has a collaboration agreement with San Francisco-based Syapse to develop software that integrates fragmented clinical, molecular, and data on treatment plans and health outcomes. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Receive RHHBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RHHBY
CUSIPN/A
CIKN/A
Phone41-61-688-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$58.12 billion
Cash Flow$2.5315 per share
Book Value$4.32 per share

Profitability

Miscellaneous

Employees82,089
Outstanding Shares6,833,380,000
Market Cap$222.63 billion
Next Earnings DateN/A
OptionableNot Optionable

Roche Holdings AG Basel (OTCMKTS:RHHBY) Frequently Asked Questions

What is Roche Holdings AG Basel's stock symbol?

Roche Holdings AG Basel trades on the OTCMKTS under the ticker symbol "RHHBY."

What price target have analysts set for RHHBY?

9 brokerages have issued 12 month price objectives for Roche Holdings AG Basel's stock. Their forecasts range from $34.00 to $34.00. On average, they anticipate Roche Holdings AG Basel's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for Roche Holdings AG Basel.

What is the consensus analysts' recommendation for Roche Holdings AG Basel?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roche Holdings AG Basel in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Roche Holdings AG Basel.

Has Roche Holdings AG Basel been receiving favorable news coverage?

News coverage about RHHBY stock has been trending somewhat positive on Monday, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Roche Holdings AG Basel earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.

Who are some of Roche Holdings AG Basel's key competitors?

What other stocks do shareholders of Roche Holdings AG Basel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Roche Holdings AG Basel investors own include Roche Holding Ltd. Genussscheine (ROG), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Pfizer (PFE), General Electric (GE), Walt Disney (DIS), Intel (INTC), Micron Technology (MU), Novartis (NVS) and NVIDIA (NVDA).

Who are Roche Holdings AG Basel's key executives?

Roche Holdings AG Basel's management team includes the folowing people:
  • Dr. Severin Schwan, CEO & Exec. Director (Age 52)
  • Dr. Alan Hippe, Chief Financial & Information Officer (Age 52)
  • Dr. Gottlieb A. Keller, Gen. Counsel & Corp. Sec. (Age 65)
  • Ms. Cristina A. Wilbur, Head of Group HR (Age 52)
  • Dr. Karl Mahler, Head of Investor Relations

Who are Roche Holdings AG Basel's major shareholders?

Roche Holdings AG Basel's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bristol John W & Co. Inc. NY (0.02%), Riverbridge Partners LLC (0.01%), Douglass Winthrop Advisors LLC (0.01%), Ferguson Wellman Capital Management Inc. (0.00%), Chartwell Investment Partners LLC (0.00%) and Scout Investments Inc. (0.00%).

Which major investors are selling Roche Holdings AG Basel stock?

RHHBY stock was sold by a variety of institutional investors in the last quarter, including Chartwell Investment Partners LLC, Bristol John W & Co. Inc. NY, New England Research & Management Inc., Scout Investments Inc., Sky Investment Group LLC, Bath Savings Trust Co and Wendell David Associates Inc..

Which major investors are buying Roche Holdings AG Basel stock?

RHHBY stock was bought by a variety of institutional investors in the last quarter, including Douglass Winthrop Advisors LLC, Riverbridge Partners LLC, Augustine Asset Management Inc., Ferguson Wellman Capital Management Inc., Valicenti Advisory Services Inc. and South Texas Money Management Ltd..

How do I buy shares of Roche Holdings AG Basel?

Shares of RHHBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Roche Holdings AG Basel's stock price today?

One share of RHHBY stock can currently be purchased for approximately $32.58.

How big of a company is Roche Holdings AG Basel?

Roche Holdings AG Basel has a market capitalization of $222.63 billion and generates $58.12 billion in revenue each year. The company earns $10.74 billion in net income (profit) each year or $2.32 on an earnings per share basis. Roche Holdings AG Basel employs 82,089 workers across the globe.

What is Roche Holdings AG Basel's official website?

The official website for Roche Holdings AG Basel is http://www.roche.com.

How can I contact Roche Holdings AG Basel?

Roche Holdings AG Basel's mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company can be reached via phone at 41-61-688-1111 or via email at [email protected]


MarketBeat Community Rating for Roche Holdings AG Basel (OTCMKTS RHHBY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  444
MarketBeat's community ratings are surveys of what our community members think about Roche Holdings AG Basel and other stocks. Vote "Outperform" if you believe RHHBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RHHBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel